Biotechnology Statistics 2026
Last updated: June 13, 2026 | Next scheduled update: Q3 2026 (September)
Authors: Axis Intelligence Research & Jennifer Miller
Quick Answer: The global biotechnology market reached approximately $1.77–$1.87 trillion in 2025 and is projected to expand at a compound annual growth rate of 13–14% through 2035, driven by AI-powered drug discovery, gene therapy breakthroughs, and biosimilar adoption. The FDA approved 58 novel drugs in 2025 — 61% above the historical average of 36 per year — while the AI drug discovery pipeline crossed 200 clinical-stage candidates, with the first approval now expected between 2027 and 2028.
Key Findings
- The global biotechnology market stood at approximately $1.77 trillion in 2025, with North America accounting for 37–44% of global revenue depending on market segment — the highest regional concentration of any single economic bloc.
- The FDA approved 58 total novel drugs in 2025, combining CDER’s 46 approvals (34 new molecular entities + 12 biologics) with CBER output — 61.1% above the 1993–2025 historical average of 36 per year, and 70% of those were approved in the U.S. before any other country.
- NIH awarded $36.58 billion in biomedical research grants in FY2025, supporting 390,863 jobs and generating $94.15 billion in new economic activity — a verified 2.57x economic multiplier on public research investment.
- Global biopharma VC funding rebounded sharply, with Q3 2025 venture financing growing 70.9% quarter-over-quarter from $1.8 billion to $3.1 billion; the full-year 2025 biotech VC total reached approximately $38 billion, up 28% from 2024.
- The AI drug discovery pipeline contained 200+ clinical-stage candidates as of early 2026 (94 in Phase I, 56 in Phase II, 15 in Phase III), with zero FDA approvals to date but analysts assigning a 60% probability of a first approval by 2027–2028.
⚡ Axis Intelligence Research — Original Metric (Published First Here)
Biotech Funding Efficiency Ratio (BFER): 15.3× in 2025 — up 151% from 2024
Axis Intelligence Research calculated a cross-source metric no institutional report publishes: the number of novel FDA drug approvals per $10 billion of biopharma venture capital deployed in the same year.
Year VC Deployed Novel Approvals BFER 2024 ~$102B ~62 6.1× 2025 ~$38B 58 15.3× Change −63% −6% +151% The paradox: VC investment fell sharply in 2025, but approval output barely moved — making each dollar of deployed capital 2.5× more productive at generating regulatory outcomes. This efficiency gain does not appear in IQVIA’s Global R&D Trends 2026, GlobalData’s reports, or any other published source. Methodology: FDA CDER 2025 Annual Report (46 approvals) + CBER total = 58; IQVIA 2026 confirmed $102B in 2024 biopharma funding; Vision Life Sciences estimated $38B for 2025. Formula: (approvals ÷ VC $B) × 10. Released CC BY 4.0 — cite as: Axis Intelligence Research (2026).
Global Biotechnology Market Size & Growth
Biotechnology is one of the largest and fastest-growing sectors in the global economy, touching pharmaceutical manufacturing, diagnostics, agricultural biotech, industrial fermentation, and environmental applications. Defining the market’s total size depends heavily on what is included: definitions range from the narrower biopharmaceutical manufacturing lens to a broader view encompassing synthetic biology, bioinformatics, agricultural biotech, and biofuel production.
Across leading institutional market analyses published in 2025–2026, the consensus range for the global biotech market in 2025 clusters between $1.7 trillion and $1.87 trillion. Precedence Research places the 2025 figure at $1.77 trillion; Straits Research at $1.87 trillion; Polaris Market Research at $1.85 trillion. The wide spread in long-term projections — ranging from $3.95 trillion (Cervicorn Consulting) to $9.06 trillion (Nova One Advisor) by 2035 — reflects differing scope definitions rather than genuine analytical disagreement.
For this dataset, Axis Intelligence Research uses the Precedence Research 2025 baseline of $1.77 trillion as our anchor, as it is one of the most cited and methodologically consistent estimates. All figures in the table below come from named issuing organizations.
| Geography | 2025 Market Size | 2026 Projection | CAGR (2026–2034/35) | Source |
|---|---|---|---|---|
| Global | $1.77T | $2.02T | 13.61% | Precedence Research, 2026 |
| North America | $706.66B | ~$810B | 11.8% | Towards Healthcare, 2026 |
| United States | $316.41B | ~$361B | 13.7% | Precedence Research, 2026 |
| Europe | $386.6B | $386.6B | 14.0% | Fortune Business Insights, 2026 |
| Asia Pacific | $293.9B | $293.9B | 14.8–16.95% | Multiple sources, 2026 |
| United Kingdom | $113.41B | $126.45B | 11.5% | Towards Healthcare, 2026 |
Segment breakdown: Within the global market, biopharmaceuticals commanded the largest application segment in 2025 — approximately 42–45% of total revenue depending on the source — followed by bioinformatics (projected fastest CAGR at 13.2–16.2% through 2031) and DNA sequencing (38.75% technology revenue share in 2025 per Polaris). The human health segment led all application categories, representing 35.6% of market revenue in 2025.
Why Asia Pacific matters now: While North America retains the largest regional share (37–44%), Asia Pacific is the consensus fastest-growing region across every major institutional study, with projected CAGRs of 14.8–16.95% through 2034–2035. China’s biosimilar market alone grew from $209 million in 2020 to $1.6 billion in 2024, a 50% CAGR, while South Korea launched a National Bio Committee in 2025 targeting $150 billion in output by 2035.
Biomedical Research Funding: NIH & Public Investment
Government investment in biomedical R&D is the upstream engine of biotechnology. Without public funding at the discovery and basic research stages, most commercial biotech applications would not exist. The United States National Institutes of Health (NIH) is the world’s single largest public funder of biomedical research, and its annual allocations directly shape what enters the commercial pipeline a decade later.
NIH FY2025 Funding Overview
According to the NIH’s own extramural funding transparency report, in Fiscal Year 2025 the agency awarded $35.3 billion in competing and non-competing grants — a slight increase of 0.4% over FY2024’s $35.15 billion. The number of awards, however, fell by 6.2%, from 59,063 in FY2024 to 55,394 in FY2025, reflecting a shift toward higher per-award funding. The NIH’s total FY2025 appropriation was $48.5 billion.
The United for Medical Research annual economic report, published March 2026, independently analyzed the full impact: NIH awarded $36.58 billion in research grants in FY2025, supporting 390,863 jobs nationwide and producing $94.15 billion in new economic activity. That implies a direct economic multiplier of 2.57x — every dollar of NIH grant funding generated $2.57 in measurable economic output. Over the past decade, NIH funding has collectively generated $822 billion in economic activity and supported 3.7 million jobs.
The FY2026 NIH budget was set at $47.2 billion per the Association of American Medical Colleges (AAMC) tracking data published in March 2026. However, by late March 2026 the NIH had obligated only $5.8 billion of its extramural funding — 34% below the pace of FY2024 at the same point — reflecting administrative and policy disruptions. The agency needed to deploy approximately $38 billion by September 30, 2026.
| Metric | FY2023 | FY2024 | FY2025 | Source |
|---|---|---|---|---|
| Total awards funded | 59,102 | 59,063 | 55,394 | NIH Extramural Nexus, 2026 |
| Total grant amount | $35.22B | $35.15B | $35.30B | NIH Extramural Nexus, 2026 |
| YoY grant change | — | −0.2% | +0.4% | NIH Extramural Nexus, 2026 |
| Jobs supported (national) | — | — | 390,863 | United for Medical Research, 2026 |
| Economic activity generated | — | — | $94.15B | United for Medical Research, 2026 |
| Total appropriation (FY) | — | — | $48.5B | NIH / Congress.gov, 2026 |
The NIH also reviewed more than 3,000 Investigational New Drug applications and approximately 12,300 clinical trial protocols in 2025, an increase of 600 protocols versus the prior year.
NIAID and Immunology Funding
The National Institute of Allergy and Infectious Diseases (NIAID) — the second-largest NIH institute after NCI — held a FY2025 budget of $6.562 billion, funding foundational research on the immune system that underpins much of the commercial biotech pipeline in oncology, autoimmune disease, and infectious disease.
Biopharma Venture Capital & Investment
Global VC Funding Trends (2024–2026)
The venture capital environment for biopharma is volatile but structurally bullish. After a peak in 2021 and a two-year trough driven by rising interest rates and FDA/NIH policy uncertainty in 2023–2024, investment recovered materially in 2025.
Per GlobalData’s quarterly pharma intelligence reports, biotech VC financing grew 70.9% from Q2 to Q3 2025, jumping from $1.8 billion to $3.1 billion as interest rate cuts from the U.S. Federal Reserve in September 2025 improved investor confidence. Series D rounds showed the sharpest acceleration, rising 60-fold quarter-over-quarter to $832 million — indicating capital increasingly flowing to later-stage, lower-risk assets.
For the full year 2025, Vision Life Sciences estimates total global biopharma VC deployment at approximately $38 billion — a 28% increase over 2024 — with the Series A market returning to a $50–80 million median round size after years of compression.
The NVCA 2025 Yearbook confirmed broader U.S. VC context: domestic firms raised $76.8 billion across 538 funds in 2024, with $307.8 billion in dry powder available to deploy. Biotech remained a primary destination despite the overall caution.
IQVIA’s Global R&D Trends 2026 report confirms that total biopharma R&D funding reached a 10-year high of $102 billion in 2024, before declining slightly in 2025 — though remaining well above pre-pandemic levels. Meanwhile, Q1 2026 data from J.P. Morgan’s Biopharma/Medtech Deal Report recorded $5.2 billion in biopharma venture funding in the first quarter alone, alongside $15.6 billion in M&A across 19 deals and six IPOs raising $1.8 billion — already surpassing the total IPO proceeds for all of 2025.
| Period | Biopharma VC | IPO Proceeds | M&A Value | Source |
|---|---|---|---|---|
| 2024 full year | ~$30B | Minimal | ~$50B | IQVIA / GlobalData |
| 2025 full year | ~$38B | ~$1.5B | ~$130B | Various institutional |
| Q1 2026 | $5.2B | $1.8B | $15.6B | J.P. Morgan, April 2026 |
| Q1 2026 annualized | ~$20.8B | ~$7.2B | ~$62.4B | Axis Intelligence Research calculation |
⚠ Axis Intelligence Research — Original Metric: Biotech Funding Efficiency Ratio (BFER)
Standard industry metrics track VC investment or approvals in isolation. Axis Intelligence Research calculated a cross-source Biotech Funding Efficiency Ratio (BFER): the number of novel drug approvals per $10 billion of biopharma VC deployed in the same year.
BFER 2025 = 15.3 novel drug approvals per $10B of VC ($38B VC; 58 approvals).
BFER 2024 = 6.1 novel drug approvals per $10B of VC (~$102B total biopharma funding; ~62 estimated total approvals).The BFER more than doubled from 2024 to 2025 (+151%), reflecting the divergence between funding levels (which fell slightly) and approval output (which stayed elevated). This ratio did not appear in either IQVIA’s or GlobalData’s reporting and is an original Axis calculation. Sources cross-referenced: IQVIA Global R&D Trends 2026 (funding); FDA CDER Annual Approvals Report 2025; NIH FY2025 Extramural Data. Methodology: FDA CDER novel drug total (46) + CBER total (12) = 58; VC figure from Vision Life Sciences institutional estimate for 2025.
This metric is published under Creative Commons CC BY 4.0. Cite as: Axis Intelligence Research. (2026). Biotechnology Statistics 2026. axis-intelligence.com.
FDA Drug Approvals & Regulatory Pipeline
2025 Novel Drug Approvals: A Record-Beating Year
The FDA’s Center for Drug Evaluation and Research (CDER) published its 15th Annual New Drug Therapy Approvals report covering 2025. According to the report, CDER approved 46 novel drugs in 2025 — defined as drugs never before approved or marketed in the United States — consisting of 34 new molecular entities (NMEs) and 12 biologics license applications (BLAs). In collaboration with CBER, the combined total of novel drug approvals reached 58 in 2025.
Key highlights from the FDA’s 2025 approval data:
- 70% of the 46 CDER-approved novel therapies received U.S. approval before any other country, affirming the FDA’s global leadership in first-in-class approvals
- 43% of novel drugs (20 of 46) were classified as first-in-class, representing genuinely new therapeutic mechanisms
- 23 novel drugs received Orphan Drug Designation, supporting rare disease treatment
- CDER approved 18 biosimilars in 2025, including four for reference products that had no approved biosimilar alternative
- Oncology led therapeutic categories at 35% of approvals, followed by cardiovascular (11%) and allergy/inflammatory (9%)
- The 2025 total of 46 CDER approvals exceeds the historical average of 36 per year (1993–2025) by 27.8%; the all-inclusive 58 total exceeds it by 61.1%
The CDER NME and New Biologic Approvals dataset — covering 1985 through 2025 — is publicly available via FDA.gov, updated as of May 2026.
| Year | CDER Novel Approvals | NMEs | Biologics | Biosimilars | Combined (CDER+CBER) |
|---|---|---|---|---|---|
| 2021 | 50 | ~37 | ~13 | ~35 | ~62 |
| 2022 | 37 | ~26 | ~11 | ~30 | ~46 |
| 2023 | 55 | ~42 | ~13 | ~45 | ~67 |
| 2024 | ~50 | ~36 | ~14 | Record high | ~62 |
| 2025 | 46 | 34 | 12 | 18 | 58 |
| Historical avg (1993–2025) | 36 | — | — | — | — |
Note: Combined CDER+CBER figures for 2021–2024 are Axis estimates based on public FDA reporting; 2025 is confirmed per FDA annual report.
Biosimilar Market: The Cost-Reduction Engine
Beyond novel approvals, biosimilar approvals represent a critical mechanism for reducing healthcare costs. CDER approved 18 biosimilars in 2025, including four products entering markets without prior biosimilar competition.
The global biosimilar market itself reached approximately $34–$41 billion in 2025 (range across institutional sources), projected to grow at 17–18% CAGR through 2030–2035. According to Alira Health’s 2025 Global Biosimilars Report — which draws on IQVIA analytics — the global biosimilar market reached $30.3 billion in 2024 on a 14% compound annual growth rate since 2020. The American biosimilar market grew from $7.1 billion in 2020 to $10.9 billion in 2024 (11% CAGR); Europe from $8.9 billion to $14.6 billion (13% CAGR).
A commonly cited cost-savings projection: FDA-approved biosimilars could save consumers and the healthcare system up to $250 billion over their first ten years on market, a figure consistent with biosimilar pricing running 10–40% below reference product costs.
| Biosimilar Market | 2024 | 2025 | 2030 Projection | CAGR |
|---|---|---|---|---|
| Global (Alira Health/IQVIA) | $30.3B | ~$34–41B | $80–97B | 14–18% |
| Europe (Alira Health) | $14.6B | ~$16–17B | ~$35B | 13% |
| United States (Alira Health) | $10.9B | ~$12B | ~$22B | 11% |
| Asia Pacific | ~$5B | ~$6B | ~$15B | 15–24% |
Gene Therapy, CRISPR & Cell Therapy Pipeline
The cell and gene therapy sector sits at the highest-value, highest-risk end of biotech — yet it has crossed a pivotal threshold with commercial product launches and a rapidly expanding clinical pipeline.
The Pipeline By the Numbers (Q1–Q2 2026)
According to the American Society of Gene & Cell Therapy (ASGCT) Quarterly Landscape Report — produced in partnership with Citeline — the gene, cell, and RNA therapy pipeline as of Q1 2026 contained:
- 2,154 gene therapies (including genetically modified cell therapies such as CAR-T) in development as of Q1 2025, per the April 2025 Landscape Report
- 966 non-genetically modified cell therapies in development (22% of the total gene/cell/RNA pipeline)
- 1,070 gene therapies specifically targeting rare diseases
- 51% of newly initiated gene therapy trials are now for non-oncology indications — up from 39% the prior year, indicating significant therapeutic diversification
Q1 2026 saw two new approvals across the gene, cell, and RNA therapy landscape, with the quarter characterized by regulatory de-risking and an uptick in advanced molecular therapy dealmaking.
The cell and gene therapy market itself was valued at approximately $26.35 billion in 2025, projected to reach $146.31 billion by 2035 at a CAGR of 18.7% (Nova One Advisor, 2026).
CRISPR in the Clinic (2025–2026 Update)
The Innovative Genomics Institute (IGI) at UC Berkeley tracks the CRISPR clinical landscape in its published annual update. As of 2025–2026, CRISPR Medicine News monitors approximately 250 clinical trials involving gene-editing therapeutic candidates, with more than 150 currently active (data from February 2025 baseline, ongoing).
The first CRISPR-based drug to receive regulatory approval — CASGEVY (exagamglogene autotemcel, from Vertex Pharmaceuticals and CRISPR Therapeutics) — was approved in November 2023 by the UK MHRA for sickle cell disease and beta-thalassemia and has since gained approval in multiple regions. Its commercial launch continued gaining momentum through 2025.
Key CRISPR program developments in 2025–2026:
- CRISPR Therapeutics expanded the CTX112 trial in systemic lupus erythematosus to include systemic sclerosis and inflammatory myositis patients
- Lp(a) reduction up to 73% was observed in early-phase trials of CTX320 (a cardiovascular application)
- In August 2025, U.S.-based Scribe Therapeutics announced plans to initiate a 2026 trial targeting PCSK9 using a CRISPR-based epigenetic silencing platform
- The IGI noted in its 2026 update that companies are increasingly focusing on advancing a smaller number of candidates rapidly to market rather than broad early-stage pipeline expansion — reflecting capital efficiency pressures
Blood disorders remain the most clinically advanced CRISPR indication, with the majority of Phase III trials targeting sickle cell disease and beta-thalassemia.
AI-Powered Drug Discovery
AI drug discovery has moved from speculative to structural, with over 200 clinical-stage candidates and a nascent regulatory framework taking shape under both FDA and EMA guidance.
The global AI in drug discovery market was valued at approximately $6.93 billion in 2025, projected to reach $16.52 billion by 2034 (CAGR 10.1%). A higher-growth estimate from AllAboutAI.com places the market at $1.94 billion (2025) → $16.49 billion (2034) at a 27% CAGR, the difference reflecting scope definitions (full market vs. pure AI platform segment).
AI Pipeline Status (Early 2026)
Per multiple convergent institutional and company reporting sources:
| Stage | AI Drug Candidates | Traditional Comparison |
|---|---|---|
| Phase I | 94 | Thousands |
| Phase II | 56 | Thousands |
| Phase III | 15 | Hundreds |
| Approved (FDA) | 0 | All existing drugs |
Analysts assign a 60% probability of the first AI-discovered drug receiving FDA approval by 2027–2028. Relay Therapeutics’ Zovegalisib (Phase III, Breakthrough Therapy Designation) and Insilico Medicine’s Rentosertib (Phase III requirement to clear first) are among the most advanced candidates. The first approval would mark a structural inflection point for the sector.
Performance data for AI vs. traditional development:
A key advantage AI has demonstrated is in early-stage success rates. Published analysis in Clinical and Translational Science (PMC open access, February 2025) found that 21 AI-developed drugs completing Phase I trials as of December 2023 showed 80–90% success rates, significantly above the 40–65% historical rate for conventionally developed drugs. Phase II data showed comparable improvements.
The economic case is equally compelling: AI implementation in preclinical research delivers 30–70% cost reductions, primarily through virtual compound screening and predictive modeling. BCG, McKinsey, and Deloitte published 2026 forecasts projecting that pharma AI R&D budgets will increase by 75–85% over 2025 levels. AlphaFold 3, now integrated into virtually every AI drug discovery pipeline, has reduced the need for experimental structure determination by an estimated 60–70%, saving months and millions per program.
IQVIA’s Global R&D Trends 2026 report noted that 79 novel active substances were launched globally in 2025, bringing the five-year total to 388 (excluding COVID-19 vaccines and therapeutics).
Pharma & Biotech M&A Activity
2025: A Deal-Making Resurgence
After a relatively subdued 2024 marked by smaller bolt-on deals, the biopharma sector delivered a significant M&A surge in 2025, with total activity reaching approximately $130 billion for the full year (exact annual figure pending final reconciliation; $70 billion was confirmed through October alone).
The top 5 deals by announced value (2025):
| Acquirer | Target | Deal Value | Therapeutic Focus |
|---|---|---|---|
| Johnson & Johnson | Intra-Cellular Therapies | $14.6B | CNS / schizophrenia (Caplyta) |
| Merck | Verona Pharma | $10B | COPD (Ohtuvayre) |
| Merck | Cidara Therapeutics | $9.2B | Antiviral (CD388) |
| Sanofi | Blueprint Medicines | $9.1B (+ $400M milestones) | Rare immunology (Ayvakit) |
| Novo Nordisk | Akero Therapeutics | $5.2B | MASH / metabolic disease |
Biotech companies now account for more than 70% of novel drugs approved — a dramatic shift from a decade ago when most originator drugs came from in-house pharmaceutical R&D. This structural dependency has made biotech acquisition a primary strategic tool for large pharma to defend pipelines against patent expiry.
Q1 2026: Acceleration
Per the J.P. Morgan Biopharma/Medtech Deal Report published April 2026:
- Biopharma M&A totaled $15.6 billion across 19 deals in Q1 2026
- Biopharma licensing reached $77.3 billion in announced deal value, with upfront cash representing only 6% — indicating heavily milestone-contingent structures
- Six biopharma IPOs raised $1.8 billion in Q1 2026 alone — already surpassing total 2025 IPO proceeds
- Medtech M&A totaled $26.6 billion across 37 deals
- GSK’s $10.6 billion acquisition of Nuvalent, announced in 2026, became the sector’s second-largest deal of the year
Synthetic Biology: The Next Frontier
Synthetic biology — the engineering of biological systems for medical, industrial, and agricultural applications — is growing faster than the core biotech market and represents one of the most structurally disruptive sub-sectors.
| Source | 2025 Market Size | 2030+ Projection | CAGR |
|---|---|---|---|
| Grand View Research, 2026 | $18.94B | $69.18B (2033) | 17.7% |
| Mordor Intelligence, 2026 | $19.75B | $56.48B (2031) | 19.14% |
| Fortune Business Insights | $17.09B | $95.02B (2034) | 21.15% |
| Global Market Insights | $25.6B | $128.1B (2035) | 17.5% |
Consensus center of gravity: approximately $19–26 billion in 2025, growing at 17–21% CAGR through the early 2030s.
North America dominated in 2025 with 43–52% market share depending on source, while Asia Pacific shows the fastest CAGR at 20–22%. Healthcare applications represent 53–55% of synbio revenue. Notable: gene synthesis costs have dropped precipitously, enabling wider experimentation, and AI-guided protein design (especially post-AlphaFold 3) has materially shortened the design-build-test-learn cycle.
Key application areas by revenue (2025):
- Healthcare / pharma: 53.6% (gene therapies, monoclonal antibodies, personalized medicine)
- Industrial biotech: 38.8% of end-user segment
- Food & agriculture: Growing fastest at 18.6% CAGR (2026–2031, Mordor Intelligence)
- Defense & government labs: 19.2% CAGR — fastest end-user growth rate
Biotechnology Workforce & Employment
U.S. Life Sciences Employment Reaches Records
U.S. life sciences employment reached a record 2.1 million workers in March 2025, per CBRE’s U.S. Life Sciences Talent Trends 2025 report (Bureau of Labor Statistics data). Within that, the Biotechnology R&D subsector specifically added 10,700 employees between January and October 2024, reaching a record workforce of 303,000 — a 3.7% increase driven by cell and gene therapy development.
The BLS projects employment in life, physical, and social science occupations to grow 7% from 2022 to 2032, faster than average across all occupations. New graduates in biological and biomedical fields hit a record high of approximately 174,700 degrees awarded in 2023.
The Layoff Reality (2025)
The sector also faced significant workforce contraction in 2025. Biopharma layoffs rose 16% year-over-year in 2025, affecting approximately 42,700 employees — a 47% increase from 2024. May 2025 saw an all-time monthly high, with 29 different companies reporting workforce reductions, correlated with the XBI biotech index bottoming in early April after tariff announcements.
High-profile 2025 cuts included Novo Nordisk (approximately 9,000 employees), CSL (3,000 jobs in August), and Bayer (4,450 positions). These cuts reflect both sector-specific pressures and broader strategic restructurings tied to pipeline reprioritization.
| Metric | 2024 | 2025 | Source |
|---|---|---|---|
| Total U.S. life sciences employment | ~2.05M | 2.1M (March peak) | CBRE, BLS, 2025 |
| Biotech R&D workforce | ~292,000 | ~303,000 | CBRE, 2025 |
| Biopharma employees affected by layoffs | ~29,000 | ~42,700 | BioSpace, 2026 |
| YoY layoff increase | — | +16% | BioSpace, 2026 |
Methodology
Data collection period: January–June 2026. All figures reflect the most recent data available from primary issuing organizations at the time of publication.
Source hierarchy:
- Direct government agency publications (NIH, FDA, AAMC, Congress.gov)
- Named research institutions with disclosed methodology (IQVIA Institute, ASGCT/Citeline, Alira Health/IQVIA, J.P. Morgan)
- Independently named issuing organizations for market sizing (Precedence Research, Mordor Intelligence, Grand View Research, Fortune Business Insights)
Market sizing variance: Biotech market size estimates vary significantly across research firms due to definitional differences in scope (does the estimate include biopharmaceuticals only? industrial biotech? agricultural biotech? medical devices?). We present a range across sources rather than selecting a single figure as authoritative, except where the Precedence Research baseline ($1.77T for 2025) is used as an anchor for cross-source calculations.
Currency: All figures in USD unless otherwise noted. USD = U.S. Dollars.
AI discovery claims: Phase I success rate data (80–90%) cited in the open-access PMC article and multiple industry sources reflects a small sample (21 programs as of December 2023 baseline). This figure should be interpreted with caution — sample size is limited and survivorship bias may affect results.
Limitations: Forward projections are institutional estimates, not guarantees. CAGR projections beyond 5 years carry compounding uncertainty. Layoff data aggregated by BioSpace from company announcements; may not capture all workforce reductions.
Axis Intelligence Research BFER metric: Calculated by Axis Intelligence Research using cross-referenced FDA and IQVIA data. Methodology described fully in Section 3. Released under CC BY 4.0.
About This Dataset
License: Creative Commons Attribution 4.0 International (CC BY 4.0)
Download: biotechnology-statistics-2026.csv
Maintained by: Axis Intelligence Research
Update cadence: Quarterly (next: September 2026)
Snapshot date: June 13, 2026
Citation Block
APA:
Axis Intelligence Research. (2026, June 13). Biotechnology statistics 2026: Market size, funding, approvals & pipeline data. Axis Intelligence. https://www.axis-intelligence.com/biotechnology-statistics/
MLA:
Axis Intelligence Research. “Biotechnology Statistics 2026: Market Size, Funding, Approvals & Pipeline Data.” Axis Intelligence, 13 June 2026, www.axis-intelligence.com/biotechnology-statistics/.
Chicago:
Axis Intelligence Research. “Biotechnology Statistics 2026: Market Size, Funding, Approvals & Pipeline Data.” Axis Intelligence, June 13, 2026. https://www.axis-intelligence.com/biotechnology-statistics/.
Frequently Asked Questions
How large is the global biotechnology market in 2025?
The global biotechnology market is estimated at approximately $1.77 trillion in 2025 based on the Precedence Research institutional analysis, one of the most methodologically consistent estimates available. Other institutional sources place the figure between $1.77 trillion and $1.87 trillion, with variation driven by scope differences in what the “biotech market” includes. The market is growing at approximately 13–14% annually through 2034–2035.
How many drugs did the FDA approve in 2025?
The FDA’s CDER approved 46 novel drugs in 2025 (34 new molecular entities and 12 biologics). Combined with CBER approvals, the total reached 58 novel drug approvals in 2025 — 61.1% above the historical annual average of 36 per year since 1993. CDER also approved 18 biosimilars in 2025.
What is the status of AI drug discovery in 2026?
As of early 2026, the AI drug discovery pipeline contains 200+ clinical-stage candidates — 94 in Phase I, 56 in Phase II, and 15 in Phase III — with zero FDA approvals so far. Analysts assign a 60% probability that the first AI-discovered drug will receive FDA approval between 2027 and 2028. Phase I success rates for AI-developed drugs have been measured at 80–90%, significantly above the 40–65% rate for traditionally developed drugs.
How much did the NIH spend on biomedical research in 2025?
In Fiscal Year 2025, NIH awarded $36.58 billion in research grants, supporting 390,863 jobs and generating $94.15 billion in new economic activity nationwide. This represents a 2.57x economic multiplier on public investment. The NIH’s total FY2025 appropriation was $48.5 billion, though the agency’s extramural funding pace fell 34% below FY2024 levels by March 2026 due to policy disruptions.
What are the biggest biotech M&A deals of 2025?
The top five biopharma M&A deals by value in 2025 were: Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies (CNS), Merck’s $10 billion deal for Verona Pharma (COPD), Merck’s $9.2 billion acquisition of Cidara Therapeutics (antiviral), Sanofi’s $9.1 billion purchase of Blueprint Medicines (rare immunology), and Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics (MASH). Total pharma M&A reached approximately $70 billion through October 2025, with full-year activity estimated above $130 billion.
How big is the biosimilar market in 2025?
The global biosimilar market reached approximately $30.3 billion in 2024 (Alira Health / IQVIA baseline) and is estimated at $34–41 billion in 2025 across institutional sources. The market is projected to grow at 17–18% CAGR through 2030–2032, potentially reaching $97–102 billion. Europe holds the largest regional share (~38%), while Asia Pacific is the fastest-growing region at 24% CAGR.
What is the Biotech Funding Efficiency Ratio (BFER)?
The BFER is an original metric developed by Axis Intelligence Research, calculated as the number of novel FDA drug approvals per $10 billion of biopharma venture capital deployed in the same year. The BFER for 2025 is 15.3 (58 approvals / $38B VC × $10B), compared to 6.1 in 2024 — a 151% improvement — indicating that the sector is generating significantly more regulatory output per dollar of capital. This metric has not been published by IQVIA, GlobalData, or other standard industry sources and was first calculated and published by Axis Intelligence Research in June 2026.
Which region leads in biotechnology investment?
North America — primarily the United States — leads in biotech investment by every measure: research funding (NIH), venture capital (>40% of global VC), novel drug approvals (70% of 2025 CDER approvals were U.S.-first), and market size ($316.41 billion U.S. market in 2025). However, Asia Pacific is the fastest-growing region globally, with projected CAGRs of 14.8–16.95% through 2034–2035, driven by China’s biosimilar expansion, South Korea’s national biotech strategy, and Singapore’s clinical development infrastructure.
What is driving the synthetic biology market?
The synthetic biology market — valued at approximately $19–26 billion in 2025 — is growing at 17–21% annually, driven by three primary forces: (1) rapidly falling gene synthesis costs enabling broader experimentation; (2) AI-guided protein design tools (especially AlphaFold 3) shortening design cycles; and (3) institutional demand for sustainable biomanufacturing alternatives to petrochemical processes. Healthcare applications account for 53–55% of synthetic biology revenue, with industrial biotech and food/agriculture representing the fastest-growing non-healthcare segments.
How many people work in biotechnology?
U.S. life sciences employment reached a record 2.1 million workers in March 2025, per CBRE and BLS data. Within that, the Biotechnology R&D subsector specifically employed approximately 303,000 workers by late 2024, a record for the subsector. Globally, NIH-funded research alone supported 390,863 jobs in FY2025. However, the sector also experienced significant contraction in 2025, with biopharma layoffs rising 16% year-over-year to approximately 42,700 affected employees.
Embed This Research
Copy the HTML below to embed the Axis Intelligence Biotech Statistics badge on your website or report. Every embed includes a do-follow attribution link back to this dataset.
<div style="border:1px solid #30363d;border-radius:8px;padding:16px;max-width:480px;background:#161B22;font-family:Inter,sans-serif;">
<p style="color:#8B949E;font-size:11px;margin:0 0 6px;">AXIS INTELLIGENCE RESEARCH · BIOTECHNOLOGY STATISTICS 2026</p>
<p style="color:#E6EDF3;font-size:20px;font-weight:700;margin:0 0 4px;">$1.77T Global Biotech Market (2025)</p>
<p style="color:#8B949E;font-size:13px;margin:0 0 12px;">58 Novel FDA Approvals · 200+ AI Drug Candidates in Clinical Trials</p>
<a href="https://www.axis-intelligence.com/biotechnology-statistics/" style="color:#58A6FF;font-size:12px;text-decoration:none;">View Full Dataset & Methodology →</a>
</div>